The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis

References

• HughesWTArmstrongDBodeyGP2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancerClin Infect Dis20023473075111850858
   PubMed Web of Science ®Google Scholar
• FreifeldAGBowEJSepkowitzKAInfectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of AmericaClin Infect Dis2011525693
   PubMed Web of Science ®Google Scholar
• MaertensJMarchettiOHerbrechtREuropean guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 updateBone Marrow Transplant20114670971820661235
   PubMed Web of Science ®Google Scholar
• de WithKSteib-BauertMKnothHHospital use of systemic antifungal drugsBMC Clin Pharmacol200551615703083
   PubMedGoogle Scholar
• StamWBAversaFKumarRNJansenJPEconomic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in ItalyValue Health20081183084118494752
   PubMed Web of Science ®Google Scholar
• NaikSLundbergJKumarRSjolinJJansenJPEconomic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in SwedenScand J Infect Dis20114350451421332286
   PubMed Web of Science ®Google Scholar
• KaskelPTuschySWagnerAEconomic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital settingAnn Hematol20088731131917929018
   PubMed Web of Science ®Google Scholar
• CaillotDCouaillierJFBernardAIncreasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computerised tomography scans in patients with neutropeniaJ Clin Oncol20011925325911134220
   PubMed Web of Science ®Google Scholar
• AsciogluSRexHBDe PauwBDefining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensusClin Infect Dis20023471411731939
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics and MethodologyGuidelines for ATC Classification and DDD AssignmentOslo, NorwayWHO2003 Available from: http://www.whocc.no/ddd/definition_and_general_consideraAccessed December 17, 2009
   Google Scholar
• WalshTJFinbergRWArndtCLiposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study GroupN Engl J Med199934076477110072411
   PubMed Web of Science ®Google Scholar
• CordonnierCPautasCMaurySEmpirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trialClin Infect Dis2009481042105119281327
   PubMed Web of Science ®Google Scholar
• GedikHŞimşekFYıldırmakMTPrimary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damageTher Clin Risk Manag20141030531224855365
   PubMed Web of Science ®Google Scholar
• SipsasNVKontoyiannisDPClinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignanciesClin Infect Dis2006421584159116652316
   PubMed Web of Science ®Google Scholar
• KimuraSIMurataTAkahoshiYEconomic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseasesEur J Clin Microbiol Infect Dis20153495196125577175
   PubMed Web of Science ®Google Scholar
• NivoixYLaunoyALutunPAdherence to recommendations for the use of antifungal agents in a tertiary care hospitalJ Antimicrob Chemother2012672506251322778159
   PubMed Web of Science ®Google Scholar
• MikulskaMNovelliAAversaFVoriconazole in clinical practiceJ Chemother201224631132723174096
   PubMed Web of Science ®Google Scholar
• GedikHŞimşekFYıldırmakMTNovel antifungal drugs against fungal pathogens: do they provide promising results for treatment?Indian J Hematol Blood Transfus20153119620525825558
   PubMed Web of Science ®Google Scholar
• Domínguez-GilAMartínIGarcía VargasMDel CastilloADíazSSánchezCEconomic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in SpainClin Drug Investig2007273197205
   Web of Science ®Google Scholar
• KaskelPTuschySWagnerAEconomic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital settingAnn Hematol20088731131917929018
   PubMed Web of Science ®Google Scholar
• KungHCJohnsonMDDrewRHSaha-ChaudhuriPPerfectJRClinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort studyCancer Med2014366767324644249
   PubMed Web of Science ®Google Scholar
• GirmeniaCFrustaciAMGentileGPosaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experienceHaematologica201297456056722102706
   PubMed Web of Science ®Google Scholar
• LiuMLiYZhangYSecondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysisPLoS One20149e11546125531544
   PubMed Web of Science ®Google Scholar
• DePBDonnellyJPProphylaxis and aspergillosis – has the principle been proven?N Engl J Med200735640941117251538
   PubMed Web of Science ®Google Scholar
• GomesMZMulanovichVEJiangYLewisREKontoyiannisDPIncidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011Antimicrob Agents Chemother201458286587324277033
   PubMed Web of Science ®Google Scholar
• HughesWTArmstrongDBodeyGP2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancerClin Infect Dis20023473075111850858
   PubMed Web of Science ®Google Scholar
• TurnerSJSenolEKaraAAl-BadriyehDDinleyiciECKongDCMCost effectiveness of caspofungin vs voriconazole for empiric therapy in TurkeyMycoses201457848949624635908
   PubMed Web of Science ®Google Scholar
• TurnerSJSenolEKaraAAl-BadriyehDDinleyiciECKongDCMPharmacoeconomic evaluation of voriconazole vs liposomal amphotericin B in empiric treatment of invasive fungal infections in TurkeyBMC Infect Dis20131356024279677
   PubMed Web of Science ®Google Scholar
• TurnerSJSenolEKaraAAl-BadriyehDKongDCMDinleyiciECPharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in TurkeyInt J Antimicrob Agents201342327628023830892
   PubMed Web of Science ®Google Scholar
• ParrMDWaiteWWHansenLAMcDanielPACost comparison of seven antibiotic combinations as empiric therapy in a simulated febrile neutropenic patientAm J Hosp Pharm19854211248424884073066
   PubMedGoogle Scholar